Abstract
A new wave of immunotherapies has considerably expanded treatment options for cutaneous melanoma patients. One strategy for boosting the anti-tumor immune response is to block inhibitory immune checkpoint proteins that restrain immune cells. Utilizing this strategy, FDA-approved immune checkpoint inhibitors targeting CTLA-4 (ipilimumab) and PD-1/PD-L1 (nivolumab, pembrolizumab) alone or in combination enhance existing immune responses and have increased patient survival and response durability.
This article is protected by copyright. All rights reserved.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.